scholarly journals Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

2017 ◽  
Vol 15 (2) ◽  
pp. 96-99 ◽  
Author(s):  
Vineet Mishra ◽  
Khusaili Gandhi ◽  
Riyankur Roy ◽  
Shaheen Hokabaj ◽  
Kunur N Shah
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Research Centre ◽  
Ferric Carboxymaltose ◽  
Childbearing Age ◽  
Deficiency Anaemia ◽  
Dose Infusion ◽  
Life Threatening ◽  
Red Blood Cell Transfusions ◽  
A Prospective Study

Background: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum iron deficiency anaemia is associated with significant maternal, foetal and infant morbidity. Current options for treatment include oral iron, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a modern treatment option. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of iron deficiency anaemia in pregnant women.Methods: A prospective study was conducted at Institute of Kidney Disease and Research Centre, Ahmedabad from January 2014 to December 2016. Antenatal women (108) with iron deficiency anaemia were the study subjects. Socio-demographic profile was recorded and anaemia was assessed based on recent haemoglobin reports. Iron deficiency was diagnosed on basis of serum ferritin value. Intravenous ferric carboxymaltose as per total correction dose (maximum 1500mg) was administered to all women; the improvement in haemoglobin levels were assessed after 3 weeks of total dose infusion. Results: Most of the women(n= 45, 41.7%), were in the age group of 27-30 years. Most of the women (n = 64, 59.3%) had moderate anaemia as per WHO guidelines. Mean haemoglobin levels significantly increased over a period of 3 weeks after Ferric carboxymaltose administrationand no serious life threatening adverse events were observed.Conclusions: Intravenous ferric carboxymaltose was safe and effective in pregnent women with iron deficiency anaemia.

scholarly journals Intravenous Iron Treatment in Pregnancy: Ferric Carboxymaltose for Correction of Iron Deficiency Anaemia

2017 ◽  
Vol 12 (2) ◽  
pp. 54-57
Author(s):  
Dilruba Zeba ◽  
Parvin Akter Khanam ◽  
Mansur Ahamed ◽  
Md Abul Khair
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Adverse Outcomes ◽  
Ferric Carboxymaltose ◽  
Childbearing Age ◽  
Deficiency Anaemia ◽  
New Treatment ◽  
A Prospective Study

Iron deficiency is the most common nutritional deficiency state of women in childbearing age. Peri-partum iron deficiency anaemia (IDA) is associated with significant maternal, fetal and infant morbidity. An effective management is needed to prevent adverse outcomes. Current options for treatment are limited; these include oral iron supplements, which are usually ineffective and poorly tolerated, and whole blood transfusion, which carries an inherent risk, should be avoided during pregnancy. Intravenous ferric carboxymaltose is a new treatment option and it is better tolerated with a good result. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of IDA in pregnant women in third trimester. It was a prospective study; 260 anaemic pregnant women received Injection ferric carboxymaltose, as a total dose of 500-1000 mg between 28 to 36 weeks of pregnancy. Safety was assessed by analyzing adverse drug reactions. Ferric carboxy maltose significantly increased Hb level (p<0.001) in all women in this study group. Increased Hb value was observed 3-4 weeks after infusion. None of the women felt worse. No serious adverse effects were found and minor side effects occurred in 34(13%) patients.Our study revealed that the Hb level increased significantly, was well tolerated and without significant side effects.Faridpur Med. Coll. J. Jul 2017;12(2): 54-57

Iron deficiency anaemia due to constitutional menorrhagia as a risk factor of infectious and inflammatory diseases and use of phytotherapeutic medicines for its treatment

2020 ◽  
pp. 51-59
Author(s):  
Yulia Ivanovna Кorshikova
Keyword(s):  
Risk Factor ◽  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Inflammatory Diseases ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Nonspecific Resistance ◽  
Deficiency Anaemia ◽  
Prophylactic Agent ◽  
Clinical Observations

The article presents clinical observations proving the importance of constitutional menorrhagia in the iron-deficiency anaemia genesis and a decrease in nonspecific resistance in women of childbearing age, as well as relevant use of phytotherapy method as a therapeutic and prophylactic agent.

scholarly journals Iron deficiency anaemia-an old enemy

2004 ◽  
Vol 10 (6) ◽  
pp. 754-760 ◽  
Author(s):  
K. Bagchi
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Eastern Mediterranean ◽  
Eastern Mediterranean Region ◽  
Public Health Problem ◽  
Micronutrient Deficiencies ◽  
Childbearing Age ◽  
Iron Supplements ◽  
Deficiency Anaemia ◽  
Targeted Interventions

Anaemia has remained a widespread public health problem in countries of the Eastern Mediterranean Region. Prevalence figures vary from a low of 17% to a high of over 70% among preschool children; from 14% to 42% among adolescents and from 11% to over 40% among women of childbearing age. Although the prevalence of anaemia has often been used as a proxy indicator for iron deficiency anaemia, this approach is not valid in settings where the etiology of anaemia is complex or unknown or where other micronutrient deficiencies of folate, vitamin B12 and vitamin A can co-exist. An integrated, multifactorial and multisectoral approach has to be adopted comprising targeted interventions to provide iron supplements to especially vulnerable segments of the population, in particular pregnant women; food-based approaches to increase iron intake through food fortification and dietary diversification; and other measures combined with iron interventions where other causes of anaemia are prevalent

scholarly journals Safety and Efficacy of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anaemia in Pregnancy - An Intervention Study Done in a Tertiary Care Hospital of Pune

2021 ◽  
Vol 8 (22) ◽  
pp. 1803-1807
Author(s):  
Anish Kumar Vishal ◽  
Dinesh Bhasin ◽  
Vidhu Dhar Dangwal ◽  
Anurakshat Bhasin
Keyword(s):  
Iron Deficiency ◽  
Blood Transfusion ◽  
Serum Ferritin ◽  
Iron Deficiency Anaemia ◽  
Tertiary Care ◽  
Ferric Carboxymaltose ◽  
Third Trimester ◽  
Deficiency Anaemia ◽  
Anaemia In Pregnancy ◽  
In Pregnancy

BACKGROUND Anaemia is one of the major public health problems in developing nations. Iron deficiency anaemia (IDA) is the commonest type of anaemia in pregnancy. Parenteral iron therapy is a recommended modality of treatment of IDA. Inj. Ferric Carboxymaltose (FCM) is a dextran free preparation which is safe, easy to deliver and better tolerated. A maximum of 1000 mg can be infused at a time. The present study was intended to assess the efficacy and safety of Inj. FCM in the treatment of iron deficiency anaemia in the second and third trimester. METHODS This prospective study was conducted at a tertiary care centre at Pune. Pregnant women with iron deficiency anaemia of moderate and severe grade were infused 1000 mg of Inj. FCM by longer infusion protocol. A total of 165 pregnant women were included in the study. The efficacy of Inj. FCM was monitored by the rise in the haemoglobin level at 03-, 06- and 08-weeks post infusion of FCM injection and serum Ferritin levels. The safety was assessed by analysing the adverse reactions. RESULTS No serious adverse reaction was recorded in any of the patients. The rise in haemoglobin (Hb) in second and third trimester of moderate and severe grade of anaemia was significant (P < 0.001). The target level of 10 g / dl was achieved in every patient. Only 03 patients received blood transfusion and that was for obstetric indications. No blood transfusion was because of anaemia per se. The rise in serum ferritin level was also statistically significant (P < 0.001). CONCLUSIONS Inj. FCM is an excellent modality to treat iron deficiency anaemia in pregnancy. It is safe and the rise of haemoglobin with correction of anaemia is satisfactory in a short span of time. In our country where only a handful of patients had regular antenatal check-up and non-compliancy and refractory anaemia is rampant, Inj. FCM is a big boon. KEYWORDS Iron Deficiency Anaemia, Inj. Ferric Carboxymaltose, Serum Ferritin, Blood Transfusion

The use of faecal immunochemical testing in the decision-making process for the endoscopic investigation of iron deficiency anaemia

2020 ◽  
Vol 58 (2) ◽  
pp. 232-239
Author(s):  
Lorena Rodriguez-Alonso ◽  
Francisco Rodriguez-Moranta ◽  
Alexandra Ruiz-Cerulla ◽  
Claudia Arajol ◽  
Katja Serra ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Postmenopausal Women ◽  
Iron Deficiency Anaemia ◽  
Cost Effective ◽  
Accurate Method ◽  
Diagnostic Study ◽  
Gi Tract ◽  
Deficiency Anaemia ◽  
Blood Haemoglobin ◽  
A Prospective Study

AbstractBackgroundBlood loss from the gastrointestinal (GI) tract is the most common cause of iron deficiency anaemia (IDA) in adult men and postmenopausal women. Gastroduodenal endoscopy (GDE) and colonoscopy are frequently recommended, despite uncertainty regarding the coexistence of lesions in the upper and lower GI tract. The faecal immunochemical test (FIT) measures the concentration of faecal haemoglobin (f-Hb) originating only from the colon or rectum. We aimed to assess whether the FIT was able to select the best endoscopic procedure for detecting the cause of IDA.MethodsA prospective study of 120 men and postmenopausal women referred for a diagnostic study of IDA were evaluated with an FIT, GDE and colonoscopy. The endoscopic finding of a significant upper lesion (SUL) or a significant bowel lesion (SBL) was considered to be the cause of the IDA.ResultsThe diagnoses were 35.0% SUL and 20.0% SBL, including 13.3% GI cancer. In the multivariate analysis, the concentration of blood haemoglobin (b-Hb) <9 g/dL (OR: 2.60; 95% CI 1.13–6.00; p = 0.025) and non-steroidal anti-inflammatory drugs NSAIDs (2.56; 1.13–5.88; p = 0.024) were associated with an SUL. Age (0.93; 0.88–0.99; p = 0.042) and f-Hb ≥ 15 μg Hb/g faeces (38.53; 8.60–172.50; p < 0.001) were associated with an SBL. A “FIT plus gastroscopy” strategy, in which colonoscopy is performed only when f-Hb ≥15 μg Hb/g faeces, would be able to detect 92.4% of lesions and be 100% accurate in the detection of cancer while avoiding 71.6% of colonoscopies.ConclusionsThe FIT is an accurate method for selecting the best endoscopy study for the evaluation of IDA. An FIT-based strategy is more cost-effective than the current bidirectional endoscopy-based strategy and could improve endoscopic resource allocation.

Sign in / Sign up

Export Citation Format

Share Document